What is Nifedipine
Nifedipine is a dihydropyridine calcium channel blocker that works by inhibiting calcium influx into vascular smooth muscle and cardiac muscle, resulting in peripheral arterial vasodilation and blood pressure reduction. 1
Mechanism of Action
Nifedipine selectively blocks voltage-dependent calcium channels in vascular smooth muscle, preventing calcium entry into cells. This inhibition of calcium influx causes:
- Peripheral arterial vasodilation - the primary mechanism for blood pressure reduction
- Decreased peripheral vascular resistance - reducing afterload on the heart
- Coronary artery dilation - improving myocardial blood flow 1, 2
Unlike non-dihydropyridine calcium channel blockers (verapamil, diltiazem), nifedipine has minimal direct effects on cardiac contractility, AV conduction, or sinus node function 2, 3. This distinguishes it from other calcium channel blockers that can cause bradycardia or AV block.
Clinical Formulations and Pharmacokinetics
Nifedipine is available in multiple formulations with distinct pharmacokinetic profiles:
- Immediate-release: 30-90 mg daily orally, short duration of action 2
- Extended-release (GITS): 30-180 mg orally, provides approximately zero-order drug delivery with plasma concentrations peaking at 2.5-5 hours and maintained for 24 hours 1, 4
- Elimination half-life: ~7 hours for extended-release versus ~2 hours for immediate-release 1
The extended-release formulation uses an osmotic pump mechanism that prevents dose dumping and maintains relatively constant plasma concentrations 4.
Clinical Uses
Nifedipine is indicated for:
- Hypertension - particularly effective due to its potent peripheral vasodilatory effects 5
- Chronic stable angina - reduces myocardial oxygen demand by decreasing afterload 6
- Vasospastic (Prinzmetal's) angina - relieves coronary artery spasm 7, 6
Side Effects
Common adverse effects relate to its vasodilating properties 2:
- Hypotension
- Dizziness and flushing
- Headache
- Peripheral edema
- Nausea and constipation
Bedtime dosing of nifedipine GITS reduces edema incidence by 91% and total adverse events by 74% compared to morning dosing 8.
Critical Safety Considerations
Immediate-Release Nifedipine in Acute Coronary Syndromes
Rapid-release, short-acting nifedipine must be avoided in unstable angina/NSTEMI in the absence of concomitant beta blockade due to increased adverse potential and mortality risk 2, 9, 10. The Holland Interuniversity Nifedipine/Metoprolol Trial was stopped early due to concern for harm with nifedipine monotherapy, though patients already on beta blockers appeared to benefit from nifedipine addition 2, 3.
Contraindications and Precautions
- Avoid in severe left ventricular dysfunction or heart failure - unlike verapamil/diltiazem which have more prominent negative inotropic effects, nifedipine's reflex tachycardia can still worsen heart failure 2
- Use caution with anesthetics - can cause severe bradyarrhythmia and hypotension when combined with anesthetic agents, particularly in elderly patients 11
- Drug interactions - grapefruit juice significantly increases nifedipine bioavailability through inhibition of presystemic metabolism 4
Dosing Considerations
For hypertension management, 60 mg once daily extended-release nifedipine provides equivalent blood pressure control to 30 mg twice daily, with the advantage of improved patient convenience and compliance 12. Bedtime administration provides superior dose-dependent efficacy and improved safety profile compared to morning dosing 8.